New Plant Constructed in Tokushima Prefecture to Serve as Production Center for Anti-cancer Drugs
Results of the Phase III Clinical Study (GEST) of TS-1 in Patients with Advanced Pancreatic Cancer Published in the Online Version of the Journal of Clinical Oncology
Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
Antitumor Agent “ABRAXANE(R) I.V. Infusion 100 mg” Approved for Additional Indications of Gastric Cancer and Non-small Cell Lung Cancer
Condition for Approval (All-Patient Enrollment) of ABRAXANE(R) I.V. Infusion 100mg Antineoplastic Removed
Results of Clinical Trial (JASPAC01) of TS-1 for Resected Pancreatic Cancer Announced at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology
